Skip to content
Contact Us
About
Leadership
Board of Directors
Scientific Advisory Board
Science & Tech
Vorolanib
DURASERT® Technology
VERISOME® Technology
Partnerships and BD Initiatives
Pipeline & Data
Pipeline
EYP-1901
Overview
Clinical Trials
Scientific Publications and Presentations
EYP-2301
Investors
Financial Information
Financials Overview
Stock Information
Analyst Coverage
Ownership Summary
Annual Reports
Earnings Releases
SEC Filings
Resources
Press Releases
Events & Presentations
IR Contact
Email Alerts
Corporate Governance
Governance Overview
Management Team
Board of Directors
Committee Composition
Contact the Board
FAQs
Form 8937
News
Careers
About
Leadership
Board of Directors
Scientific Advisory Board
Science & Tech
Vorolanib
DURASERT® Technology
VERISOME® Technology
Partnerships and BD Initiatives
Pipeline & Data
Pipeline
EYP-1901
Overview
Clinical Trials
Scientific Publications and Presentations
EYP-2301
Investors
Financial Information
Financials Overview
Stock Information
Analyst Coverage
Ownership Summary
Annual Reports
Earnings Releases
SEC Filings
Resources
Press Releases
Events & Presentations
IR Contact
Email Alerts
Corporate Governance
Governance Overview
Management Team
Board of Directors
Committee Composition
Contact the Board
FAQs
Form 8937
News
Careers
Home
About
Science & Tech
Pipeline & Data
Investors
News
Careers
Contact Us
Menu
Home
About
Science & Tech
Pipeline & Data
Investors
News
Careers
Contact Us
WET AMD Phase 2 Clinical Trial – DAVIO 2
Clinical Trials - EYP-1901
Phase 1 DAVIO Clinical Trial Results in Wet AMD
Phase 1 DAVIO clinical trial demonstrated a favorable safety profile, meeting the primary safety endpoint
View Data
Phase 1 DAVIO Clinical Trial In Wet AMD – Subgroup Analysis
EYP-1901 Is Advancing As A Potential Maintenance Therapy In Wet AMD – “Treat to Maintain”
View Data
WET AMD Phase 2 Clinical Trial – DAVIO 2
The Phase 2 DAVIO 2 clinical trial for EYP-1901 in wet AMD was designed to support initiation of Phase 3 clinical trials in 2H 2024
View Data
Non-proliferative Diabetic Retinopathy – Phase 2 Clinical Trial (PAVIA)
Randomized Double-Masked Single Injection With Sham Control As A 9-Month Treatment In NPDR
View Data